On the period of development of neuroleptic cardiomyopathy

DOI: https://doi.org/10.29296/25877305-2019-09-05
Issue: 
9
Year: 
2019

V. Volkov, Candidate of Medical Sciences Tver Center of Forensic Examinations

Comparative analysis of the data obtained in the morphometric study of the heart at different levels of its organization in neuroleptic cardiomyopathy, on the one hand, and in different periods of antipsychotic therapy, on the other, has determined the timing of the onset of this iatrogenic complication caused by the side cardiotoxic effect of neuroleptic drugs.
Keywords: 
cardiology
neuroleptics
antipsychotic therapy
neuroleptic cardiomyopathy
onset of development

References: 
  1. Avtandilov G.G. Meditsinskaja morfometrija / M.: Meditsina, 1990; 384 s. [Avtandilov G.G. Medical morphometry: management / M.: Meditsina, 1990; 384 p. (in Russ.)].
  2. Avtandilov G.G. Osnovy kolichestvennoj patologicheskoj anatomii: ucheb. Posobie / M.: Meditsina, 2002; 240 s. [Avtandilov G.G. Fundamentals of quantitative pathological anatomy / M.: Meditsina, 2002; 240 p. (in Russ.)].
  3. Volkov V.P. Klinicheskaja harakteristika nejrolepticheskoj kardiomiopatii. Aktual'nye problemy terapevticheskoj kliniki: kollektivnaja nauch. monografija. Pod red. V.P.Volkova / Novosibirsk: SibAK, 2013; Gl. 4: s. 64–116 [Volkov V.P. Clinical characteristic of an antipsychotic cardiomyopathy. Actual problems of therapeutic clinic: collective scientific monograph. V.P. Volkov (ed.) / Novosibirsk: SibAK, 2013; Ch. 4: p. 94–116 (in Russ.)].
  4. Volkov V.P. Kolichestvennaja patomorfologija spetsificheskih dilatatsionnyh kardiomiopatij / Tver': Triada, 2016; 132 s. [Volkov V.P. Quantitative pathomorphology of specific dilated cardiomyopathies / Tver: Triada, 2016; 132 p. (in Russ.)].
  5. Volkov V.P. Morfometricheskie aspekty morfogeneza nejrolepticheskoj kardiomiopatii // Ros. kardiol. zhurn. – 2012; 3 (95): 68–73 [Volkov VP. Morphometric aspects of a morphogenesis of an antipsychotic cardiomyopathy // Ros. J. Cardiol. – 2012; 3: 68–73 (in Russ.)].
  6. Volkov V.P. Novyj metod organometrii serdtsa. Paraklinicheskie distsipliny: novye metody i diagnosticheskie vozmozhnosti: kollektivnaja monografija. Pod red. V.P. Volkova / Novosibirsk: SibAK, 2014; Gl. 4: s. 78–100 [Volkov V.P. New method of an organometry of heart. Paraclinical disciplines: new methods and diagnostic possibilities: collective monograph. V.P. Volkov (ed.) / Novosibirsk: SiBAK, 2014; Ch. 4: p. 78–100 (in Russ.)].
  7. Volkov V.P. Fenotiazinovaja dilatatsionnaja kardiomiopatija: nekotorye aspekty kliniki i morfologii // Klin. meditsina. – 2009; 87 (8): 13–6 [Volkov V.P. Phenothiazine dilated cardiomyopathy: some aspects of clinic and morphology // Clin. Med. – 2009; 87 (8): 13–6 (in Russ.)].
  8. Gutsol A.A., Kondrat'ev B.Ju. Prakticheskaja morfometrija organov i tkanej / Tomsk: Izd-vo Tomskogo un-ta, 1988; 136 s. [Gutsol AA, Kondratyev BYu. Practical morphometry of organs and tissues / Tomsk: Tomsk. Univer. Publ., 1988; 136 p. (in Russ.)].
  9. Kljushin D.A., Petunin Ju.I. Dokazatel'naja meditsina. Primenenie statisticheskih metodov / M.: Dialektika: Vil'jams, 2008; 320 s. [Klyushin D.A., Petunin Yu.I. Evidential medicine. Application of statistical methods / M.: Dialectics Publ., 2008; 320 p. (in Russ.)].
  10. Alawami M., Wasywich C., Cicovic A. et al. A systematic review of clozapine induced cardiomyopathy // Int. J. Cardiol. – 2014; 176 (2): 315–20. DOI: 10.1016/j.ijcard.2014.07.103.
  11. Coulter D., Bate A., Meyboom R. et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study // BMJ. – 2001; 322 (7296): 1207–9. DOI: 10.1136/bmj.322.7296.1207.
  12. Buckley N., Sanders P. Cardiovascular adverse effects of antipsychotic drugs // Drug Saf. – 2000; 23 (3): 215–28. http://dx.doi.org/10.2165/00002018-200023030-00004.
  13. Makhoul B., Hochberg I., Rispler S. et al. Dilated cardiomyopathy: an unusual complication of clozapine therapy // Nat. Clin. Pract. Cardiovasc. Med. – 2008; 5 (9): 566–70. DOI: 10.1038/ncpcardio1292.
  14. Tanner M., Culling W. Clozapine associated dilated cardiomyopathy // Postgrad. Med. J. – 2003; 79 (933): 412–3. DOI: 10.1136/pmj.79.933.412.
  15. De Berardis D., Serroni N., Campanella D. et al. Update on the adverse effects of clozapine: focus on myocarditis // Curr. Drug Saf. – 2012; 7 (1): 55–62. DOI: 10.2174/157488612800492681.